This company has been marked as potentially delisted and may not be actively trading. NASDAQ:INZY Inozyme Pharma (INZY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Inozyme Pharma Stock (NASDAQ:INZY) Get Inozyme Pharma alerts:Sign Up Key Stats Today's Range$4.00▼$4.0050-Day Range$3.95▼$4.0052-Week Range$0.93▼$4.00VolumeN/AAverage Volume2.79 million shsMarket Capitalization$258.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. Read More Receive INZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INZY Stock News HeadlinesCervoMed appoints Matthew Winton as chief commercial, business officerOctober 7, 2025 | msn.comInozyme Pharma Inc News (INZY) - Investing.comJuly 2, 2025 | investing.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.May 30 at 1:00 AM | Porter & Company (Ad)BioMarin Announces Completion of Acquisition of InozymeJuly 1, 2025 | prnewswire.comInozyme Pharma Inc Ordinary SharesJune 21, 2025 | morningstar.comMInozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of StockholdersJune 20, 2025 | globenewswire.comInozyme Pharma Reports Increased Loss Amid Strategic FocusJune 9, 2025 | tipranks.comBMRN to Acquire Inozyme PharmaMay 22, 2025 | finance.yahoo.comSee More Headlines INZY Stock Analysis - Frequently Asked Questions How were Inozyme Pharma's earnings last quarter? Inozyme Pharma, Inc. (NASDAQ:INZY) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.01. When did Inozyme Pharma IPO? Inozyme Pharma (INZY) raised $105 million in an initial public offering on Friday, July 24th 2020. The company issued 7,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Inozyme Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inozyme Pharma investors own include Salesforce (CRM), Home Depot (HD), Chevron (CVX), CocaCola (KO), Meta Platforms (META), Qualcomm (QCOM) and AbbVie (ABBV). Company Calendar Last Earnings5/14/2025Today5/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INZY CIK1693011 Webwww.inozyme.com Phone857-330-4340FaxN/AEmployees50Year Founded2016Profitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$102.02 million Net MarginsN/A Pretax MarginN/A Return on Equity-159.93% Return on Assets-82.48% Debt Debt-to-Equity Ratio0.65 Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book4.44Miscellaneous Outstanding Shares64,562,000Free Float56,698,000Market Cap$258.25 million OptionableOptionable Beta2.27 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:INZY) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersHer 0DTE system hits 87% of the timeA Wall Street insider's 0DTE options system claims an 87 percent hit rate by tracking where institutional mone...Trade To Close | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredPre-IPO Warning: SPCX [Watch Now!]Tech investor James Altucher - who called Netflix, Facebook, and Bitcoin early - says the SpaceX IPO (Ticker: ...Paradigm Press | SponsoredThe SpaceX S-1 changes everythingSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredWhen SpaceX goes public your retirement pays the priceWhen SpaceX files its S-1, institutions will liquidate holdings, rebalance portfolios, and free up capital for...Reagan Gold Group | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman, and Nvidia CEO Jensen Huang may hold the answer to ...Altimetry | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
